BR112019006194A2 - composições que compreendem um ligante de ligação ao receptor de canabinóides - Google Patents

composições que compreendem um ligante de ligação ao receptor de canabinóides

Info

Publication number
BR112019006194A2
BR112019006194A2 BR112019006194A BR112019006194A BR112019006194A2 BR 112019006194 A2 BR112019006194 A2 BR 112019006194A2 BR 112019006194 A BR112019006194 A BR 112019006194A BR 112019006194 A BR112019006194 A BR 112019006194A BR 112019006194 A2 BR112019006194 A2 BR 112019006194A2
Authority
BR
Brazil
Prior art keywords
receptor binding
cannabinoid receptor
compositions
binding binder
binder
Prior art date
Application number
BR112019006194A
Other languages
English (en)
Inventor
Günther Bernhard
Löscher Frank
Steven Philipp
Krösser Son­Ja
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of BR112019006194A2 publication Critical patent/BR112019006194A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Abstract

a presente invenção proporciona uma composição farmacêutica que compreende: a) uma quantidade terapeuticamente efetiva de pelo menos um ligante de ligação ao receptor canabinóide, e b) um veículo líquido que compreende pelo menos um alcano semifluorado; bem como o uso dessas composições farmacêuticas na forma de um medicamento.
BR112019006194A 2016-09-28 2017-09-27 composições que compreendem um ligante de ligação ao receptor de canabinóides BR112019006194A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16191194 2016-09-28
EP17168172 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (1)

Publication Number Publication Date
BR112019006194A2 true BR112019006194A2 (pt) 2019-06-18

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019006194A BR112019006194A2 (pt) 2016-09-28 2017-09-27 composições que compreendem um ligante de ligação ao receptor de canabinóides

Country Status (10)

Country Link
US (1) US20190343793A1 (pt)
EP (2) EP3698785A1 (pt)
JP (1) JP2019534867A (pt)
KR (1) KR20190060787A (pt)
CN (1) CN109803650A (pt)
AU (1) AU2017333420A1 (pt)
BR (1) BR112019006194A2 (pt)
CA (1) CA3036313A1 (pt)
MX (1) MX2019003544A (pt)
WO (1) WO2018060282A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547323B1 (en) 2010-03-17 2016-01-27 Novaliq GmbH Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP4342537A2 (en) 2012-09-12 2024-03-27 Novaliq GmbH Semifluorinated alkane compositions
EP4234523A1 (en) 2015-09-30 2023-08-30 Novaliq GmbH Semifluorinated compounds for ophthalmic administration
JP6602964B2 (ja) 2015-09-30 2019-11-06 ノバリック ゲーエムベーハー 半フッ素化化合物およびその組成物
AU2017329772B2 (en) 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
US10732712B2 (en) * 2016-12-27 2020-08-04 Facebook Technologies, Llc Large scale integration of haptic devices
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
WO2019071008A1 (en) 2017-10-04 2019-04-11 Pneuma Respiratory, Inc. ELECTRONIC DEVICE FOR DELIVERY OF LINEAR SHAPE ADMINISTRATION OPERATED BY BREATHING AND METHODS OF USE
JP2021502178A (ja) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US11117869B2 (en) * 2019-02-01 2021-09-14 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia
IL301902A (en) * 2020-10-05 2023-06-01 Max Biology Co Ltd Compounds contain cannabinoids for use in the treatment and prevention of disease
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
EP4359046A1 (en) 2021-06-22 2024-05-01 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
WO2023064477A1 (en) * 2021-10-13 2023-04-20 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
AU2007281918A1 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
WO2010051541A2 (en) 2008-10-31 2010-05-06 The University Of Mississippi Compositions containing delta-9-thc-amino acid esters and process of preparation
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
CA2883002C (en) * 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
EP4342537A2 (en) * 2012-09-12 2024-03-27 Novaliq GmbH Semifluorinated alkane compositions
WO2015053829A1 (en) 2013-10-09 2015-04-16 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
ES2784229T3 (es) 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Also Published As

Publication number Publication date
CN109803650A (zh) 2019-05-24
EP3698785A1 (en) 2020-08-26
CA3036313A1 (en) 2018-04-05
KR20190060787A (ko) 2019-06-03
US20190343793A1 (en) 2019-11-14
EP3518921A1 (en) 2019-08-07
AU2017333420A1 (en) 2019-04-04
EP3518921B1 (en) 2021-08-11
JP2019534867A (ja) 2019-12-05
WO2018060282A1 (en) 2018-04-05
MX2019003544A (es) 2019-09-19

Similar Documents

Publication Publication Date Title
BR112019006194A2 (pt) composições que compreendem um ligante de ligação ao receptor de canabinóides
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
DOP2017000109A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
DOP2016000125A (es) MODULADORES DE ROR GAMMA (RORy)
CL2016002772A1 (es) Composiciones de insulina de rápida acción
BR112018013530A2 (pt) ?peptídeo isolado, polinucleotídeo e composição farmacêutica?
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
CL2019000266A1 (es) Composición de cannabis.
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
CL2016000925A1 (es) Inhibidores de bromodominio
BR112016002233A2 (pt) composições de adoçante
BR112019006642A2 (pt) antagonistas multiméricos de e-selectina altamente potentes
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
BR112017006137A2 (pt) formulação que contém biotensoativo
MY165124A (en) Semifluorinated alkane compositions
BR112018002983A2 (pt) composição compreendendo uma lactama e um álcool
CO2018005753A2 (es) Composición hemostática
CO2019000787A2 (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración
BR112015026289A2 (pt) selantes adesivos contendo alcoxissilila com viscosidade intrinsecamente reduzida
BR112015023387A2 (pt) composições lipídicas de racecodotril
CL2019003430A1 (es) Tratamiento conjunto antineoplásico.
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2741 DE 18/07/2023.